FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Valérie Audinot

Research Profile

Anatomy

CHO Cells

Living Beings

Chemicals & Drugs

Physiology

Binding, Competitive

Concepts & Ideas

Co-author Network

Publications

TOP 3
Antoine Bril; Murielle Combettes; Valérie Audinot
[G-protein-coupled receptors, the beginning of a new era for therapeutic innovation].
Mark J Millan; O Muller; Adrian Newman-Tancredi; Clotilde Mannoury La Cour; Philippe Marin; Valérie Audinot; Joël Bockaert; Jean A Boutin; Benjamin Chanrion; Didier Cussac; Anne Dekeyne; Benjamin Di Cara; Delphine S Dupuis; Ralf JOckers; Maud Kamal; Gilbert Lavielle
S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
Odile Della Zuana; Alain Ktorza; Viviane Levenez; Jean-Louis Nahon; F Presse; Valérie Audinot; Jean A Boutin
Peripheral injections of melanin-concentrating hormone receptor 1 antagonist S38151 decrease food intake and body weight in rodent obesity models.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Valérie Audinot (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Antoine Bril; Murielle Combettes; Valérie Audinot
[G-protein-coupled receptors, the beginning of a new era for therapeutic innovation].
Médecine sciences : M/S 2012;28(10):799-800.
2012: Mark J Millan; O Muller; Adrian Newman-Tancredi; Clotilde Mannoury La Cour; Philippe Marin; Valérie Audinot; Joël Bockaert; Jean A Boutin; Benjamin Chanrion; Didier Cussac; Anne Dekeyne; Benjamin Di Cara; Delphine S Dupuis; Ralf JOckers; Maud Kamal; Gilbert Lavielle
S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
The Journal of pharmacology and experimental therapeutics 2012;340(3):750-64.
2012: Odile Della Zuana; Alain Ktorza; Viviane Levenez; Jean-Louis Nahon; F Presse; Valérie Audinot; Jean A Boutin
Peripheral injections of melanin-concentrating hormone receptor 1 antagonist S38151 decrease food intake and body weight in rodent obesity models.
Frontiers in endocrinology 2012;3():160.
2010: Mélanie Liutkus; Frédéric Caijo; Anne-Lise Girard; Erwan Ayral; Valérie Audinot; Jean A Boutin; Pierre Renard; Daniel-Henri Caignard; Catherine Dacquet; Alain Ktorza; Paul Mosset; René Grée
Synthesis of new 8(S)-HETE analogs and their biological evaluation as activators of the PPAR nuclear receptors.
Journal of enzyme inhibition and medicinal chemistry 2010;25(5):653-72.
2010: Christophe Mésangeau; Basile Pérès; Carole Descamps-François; Philippe CHAVATTE; Valérie Audinot; Sophie Coumailleau; Jean A Boutin; Philippe Delagrange; Caroline Bennejean; Pierre Renard; Daniel-Henri Caignard; Pascal Berthelot; Saïd Yous
Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT(1) melatoninergic ligands.
Bioorganic & medicinal chemistry 2010;18(10):3426-36.
2009: Valérie Audinot; Odile Della Zuana; Nelly Fabry; C Ouvry; Olivier Nosjean; JM Henlin; Jean-Luc Fauchère; Jean A Boutin
S38151 [p-guanidinobenzoyl-[Des-Gly(10)]-MCH(7-17)] is a potent and selective antagonist at the MCH(1) receptor and has anti-feeding properties in vivo.
Peptides 2009;30(11):1997-2007.
2009: Sophie Durieux; Angéline Chanu; Christophe Bochu; Valérie Audinot; Sophie Coumailleau; Jean A Boutin; Philippe Delagrange; Daniel H Caignard; Caroline Bennejean; Pierre Renard; Daniel Lesieur; Pascal Berthelot; Saïd Yous
Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II.
Bioorganic & medicinal chemistry 2009;17(8):2963-74.
2008: Sophie Poissonnier-Durieux; Mohamed Ettaoussi; Basile Pérès; Jean A Boutin; Valérie Audinot; Caroline Bennejean; Philippe Delagrange; Daniel-Henri Caignard; Pierre Renard; Pascal Berthelot; Daniel Lesieur; Saïd Yous
Synthesis of 3-phenylnaphthalenic derivatives as new selective MT(2) melatoninergic ligands.
Bioorganic & medicinal chemistry 2008;16(18):8339-48.
2008: Valérie Audinot; Anne Bonnaud; Line Grandcolas; Marianne Rodriguez; Nadine Nagel; Jean-Pierre Galizzi; Ales Balik; Sophie Messager; David G Hazlerigg; Perry Barrett; Philippe Delagrange; Jean A Boutin
Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors.
Biochemical pharmacology 2008;75(10):2007-19.
2008: Mark J Millan; Clotilde Mannoury La Cour; Francesca Novi; Roberto Maggio; Valérie Audinot; Adrian Newman-Tancredi; Didier Cussac; Valérie Pasteau; Jean-A Boutin; T Dubuffet; Gilbert Lavielle
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
The Journal of pharmacology and experimental therapeutics 2008;324(2):587-99.
2007: Nicolas Chartrel; ALVEAR-PEREZ RODRIGO; Jérôme Leprince; Xavier Iturrioz; Annabelle Reaux-Le Goazigo; Valérie Audinot; Pascale Chomarat; F Coge; Olivier Nosjean; M Rodriguez; Jean-Pierre Galizzi; Jean A Boutin; Hubert Vaudry; Catherine Llorens-Cortes
Comment on "Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake".
Science (New York, N.Y.) 2007;315(5813):766; author reply 766.
2006: C Allera-Moreau; Pascale Chomarat; Valérie Audinot; Francis Cogé; M Gillard; Y Martineau; Jean A Boutin; Anne-Catherine Prats
The use of IRES-based bicistronic vectors allows the stable expression of recombinant G-protein coupled receptors such as NPY5 and histamine 4.
Biochimie 2006;88(6):737-46.
2006: Marie-Françoise Boussard; Sandrine Truche; Anne Rousseau-Rojas; Sylvie Briss; Sophie Descamps; Monique Droual; Michel Wierzbicki; Gilles Ferry; Valérie Audinot; Philippe Delagrange; Jean A Boutin
New ligands at the melatonin binding site MT(3).
European journal of medicinal chemistry 2006;41(3):306-20.
2005: Jean A Boutin; Valérie Audinot; Gilles Ferry; Philippe Delagrange
Molecular tools to study melatonin pathways and actions.
Trends in pharmacological sciences 2005;26(8):412-9.
2005: Philippe Beauverger; Marianne Rodriguez; Jean-Paul Nicolas; Valérie Audinot; Véronique Lamamy; Sandra Dromaint; Nadine Nagel; Christelle Macia; Odile Léopold; Jean-Pierre Galizzi; Daniel-Henri Caignard; Ignacio Aldana; Antonio Monge; Pascale Chomarat; Jean A Boutin
Functional characterization of human neuropeptide Y receptor subtype five specific antagonists using a luciferase reporter gene assay.
Cellular signalling 2005;17(4):489-96.
2004: Carlos Larraya; Jérôme Guillard; Pierre Renard; Valérie Audinot; Jean A Boutin; Philippe Delagrange; Caroline Bennejean; Marie-Claude Viaud-Massuard
Preparation of 4-azaindole and 7-azaindole dimers with a bisalkoxyalkyl spacer in order to preferentially target melatonin MT1 receptors over melatonin MT2 receptors.
European journal of medicinal chemistry 2004;39(6):515-26.
2004: Odile Della Zuana; L Revereault; Annette G Beck-Sickinger; A Monge; Daniel-Henri Caignard; Jean-Luc Fauchère; JM Henlin; Valérie Audinot; Jean A Boutin; S Chamorro; Michel Félétou; Nigel Levens
A potent and selective NPY Y5 antagonist reduces food intake but not through blockade of the NPY Y5 receptor.
International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 2004;28(4):628-39.
2004: François Mailliet; Valérie Audinot; Benoît Malpaux; Anne Bonnaud; Philippe Delagrange; Martine Migaud; Perry Barrett; Marie-Claude Viaud-Massuard; Daniel Lesieur; François Lefoulon; Pierre Renard; Jean A Boutin
Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors.
Biochemical pharmacology 2004;67(4):667-77.
2003: Valérie Audinot; François Mailliet; Chantal Lahaye-Brasseur; Anne Bonnaud; Aude Le Gall; Christophe Amossé; Sandra Dromaint; Marianne Rodriguez; Nadine Nagel; Jean-Pierre Galizzi; Benoît Malpaux; Gérald Guillaumet; Daniel Lesieur; François Lefoulon; Pierre Renard; Philippe Delagrange; Jean A Boutin
New selective ligands of human cloned melatonin MT1 and MT2 receptors.
Naunyn-Schmiedeberg's archives of pharmacology 2003;367(6):553-61.
2003: Isabelle Charton; Franck Suzenet; Jean A Boutin; Valérie Audinot; Philippe Delagrange; Caroline Bennejean; Pierre Renard; Gérald Guillaumet
Synthesis of 5-substituted-2,3-dihydro-1,4-benzoxathiins: biological evaluation as melatonin receptors ligands.
Journal of enzyme inhibition and medicinal chemistry 2003;18(2):187-93.
2003: C Mesangeau; Saïd Yous; Philippe CHAVATTE; Gilles Ferry; Valérie Audinot; Jean A Boutin; Philippe Delagrange; Caroline Bennejean; Pierre Renard; Daniel Lesieur
Design, synthesis and in vitro evaluation of novel benzo[b]thiophene derivatives as serotonin N-acetyltransferase (AANAT) inhibitors.
Journal of enzyme inhibition and medicinal chemistry 2003;18(2):119-25.
2003: Carole Descamps-François; Saïd Yous; Philippe CHAVATTE; Valérie Audinot; Anne Bonnaud; Jean A Boutin; Philippe Delagrange; Caroline Bennejean; Pierre Renard; Daniel Lesieur
Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands.
Journal of medicinal chemistry 2003;46(7):1127-9.
2003: Saïd Yous; Sophie Durieux-Poissonnier; Emmanuelle Lipka-Belloli; Halim Guelzim; Christophe Bochu; Valérie Audinot; Jean A Boutin; Philippe Delagrange; Caroline Bennejean; Pierre Renard; Daniel Lesieur
Design and synthesis of 3-phenyl tetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands.
Bioorganic & medicinal chemistry 2003;11(5):753-9.
2003: Marianne Rodriguez; Valérie Audinot; Sandra Dromaint; Christelle Macia; Véronique Lamamy; Philippe Beauverger; Herve RIQUE; Jérôme Imbert; Jean-Paul Nicolas; Jean A Boutin; Jean-Pierre Galizzi
Molecular identification of the long isoform of the human neuropeptide Y Y5 receptor and pharmacological comparison with the short Y5 receptor isoform.
The Biochemical journal 2003;369(Pt 3):667-73.
2003: Zhi-Chao Dang; Valérie Audinot; Socrates E Papapoulos; Jean A Boutin; Clemens W G M Löwik
Peroxisome proliferator-activated receptor gamma (PPARgamma ) as a molecular target for the soy phytoestrogen genistein.
The Journal of biological chemistry 2003;278(2):962-7.
2002: N Beaurain; C Mésangeau; Philippe CHAVATTE; Gilles Ferry; Valérie Audinot; Jean A Boutin; Philippe Delagrange; Caroline Bennejean; Saïd Yous
Design, synthesis and in vitro evaluation of novel derivatives as serotonin N-acetyltransferase inhibitors.
Journal of enzyme inhibition and medicinal chemistry 2002;17(6):409-14.
2002: Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; Jean-Paul Nicolas; Frédéric De Ceuninck; Jean A Boutin; Mark J Millan
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
The Journal of pharmacology and experimental therapeutics 2002;303(2):805-14.
2002: Mark J Millan; Lisa Maiofiss; Didier Cussac; Valérie Audinot; Jean A Boutin; Adrian Newman-Tancredi
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
The Journal of pharmacology and experimental therapeutics 2002;303(2):791-804.
2002: Valérie Audinot; Nelly Fabry; Jean-Paul Nicolas; Philippe Beauverger; Adrian Newman-Tancredi; Mark J Millan; Anne Try; Frédéric Bornancin; Emmanuel Canet; Jean A Boutin
Ligand modulation of [35S]GTPgammaS binding at human alpha(2A), alpha(2B) and alpha(2C) adrenoceptors.
Cellular signalling 2002;14(10):829-37.
2002: Laurence Maulon-Feraille; Odile Della Zuana; Thomas Suply; Carole Rovere-Jovene; Valérie Audinot; Nigel Levens; Jean A Boutin; Jacques Duhault; Jean-Louis Nahon
Appetite-boosting property of pro-melanin-concentrating hormone(131-165) (neuropeptide-glutamic acid-isoleucine) is associated with proteolytic resistance.
The Journal of pharmacology and experimental therapeutics 2002;302(2):766-73.
2002: Valérie Audinot; Chantal Lahaye; Thomas Suply; Carole Rovère-Jovène; Marianne Rodriguez; Jean-Paul Nicolas; Philippe Beauverger; Bruno Cardinaud; Jean-Pierre Galizzi; Jean-Luc Fauchère; Jean-Louis Nahon; Jean A Boutin
SVK14 cells express an MCH binding site different from the MCH1 or MCH2 receptor.
Biochemical and biophysical research communications 2002;295(4):841-8.
2002: Valérie Wallez; Sophie Durieux-Poissonnier; Philippe CHAVATTE; Jean A Boutin; Valérie Audinot; Jean-Paul Nicolas; Caroline Bennejean; Philippe Delagrange; Pierre Renard; Daniel Lesieur
Synthesis and structure-affinity-activity relationships of novel benzofuran derivatives as MT(2) melatonin receptor selective ligands.
Journal of medicinal chemistry 2002;45(13):2788-800.
2002: Jean A Boutin; Thomas Suply; Valérie Audinot; Marianne Rodriguez; Philippe Beauverger; Jean-Paul Nicolas; Jean-Pierre Galizzi; Jean-Luc Fauchère
Melanin-concentrating hormone and its receptors: state of the art.
Canadian journal of physiology and pharmacology 2002;80(5):388-95.
2002: Mark J Millan; Adrian Newman-Tancredi; S Lochon; Manuelle Touzard; S Aubry; Valérie Audinot
Specific labelling of serotonin 5-HT(1B) receptors in rat frontal cortex with the novel, phenylpiperazine derivative, [3H]GR125,743. A pharmacological characterization.
Pharmacology, biochemistry, and behavior 2002;71(4):589-98.
2001: Marianne Rodriguez; Philippe Beauverger; Isabelle Naime; Herve RIQUE; C Ouvry; S Souchaud; Sandra Dromaint; Nadine Nagel; Thomas Suply; Valérie Audinot; Jean A Boutin; Jean-Pierre Galizzi
Cloning and molecular characterization of the novel human melanin-concentrating hormone receptor MCH2.
Molecular pharmacology 2001;60(4):632-9.
2001: Thomas Suply; Odile Della Zuana; Valérie Audinot; Marianne Rodriguez; Philippe Beauverger; Jacques Duhault; Emmanuel Canet; Jean-Pierre Galizzi; Jean-Louis Nahon; Nigel Levens; Jean A Boutin
SLC-1 receptor mediates effect of melanin-concentrating hormone on feeding behavior in rat: a structure-activity study.
The Journal of pharmacology and experimental therapeutics 2001;299(1):137-46.
2001: Valérie Audinot; Adrian Newman-Tancredi; Didier Cussac; M J Millan
Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)(1B) and h5-HT(1D) receptors.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2001;25(3):410-22.
2001: Valérie Audinot; Chantal Lahaye; Thomas Suply; Philippe Beauverger; Marianne Rodriguez; Jean-Pierre Galizzi; Jean-Luc Fauchère; Jean A Boutin
[125I]-S36057: a new and highly potent radioligand for the melanin-concentrating hormone receptor.
British journal of pharmacology 2001;133(3):371-8.
2001: Mark J Millan; Didier Cussac; G Milligan; C Carr; Valérie Audinot; Alain Gobert; Françoise Lejeune; Jean-Michel Rivet; Mauricette Brocco; Delphine Duqueyroix; Jean-Paul Nicolas; Jean A Boutin; Adrian Newman-Tancredi
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.
The Journal of pharmacology and experimental therapeutics 2001;297(3):876-87.
2001: Valérie Audinot; Philippe Beauverger; Chantal Lahaye; Thomas Suply; Marianne Rodriguez; C Ouvry; Véronique Lamamy; Jérôme Imbert; Herve RIQUE; Jean-Louis Nahon; Jean-Pierre Galizzi; Emmanuel Canet; Nigel Levens; JL Fauchere; Jean A Boutin
Structure-activity relationship studies of melanin-concentrating hormone (MCH)-related peptide ligands at SLC-1, the human MCH receptor.
The Journal of biological chemistry 2001;276(17):13554-62.
2001: Francis Cogé; Sophie-Pénélope Guénin; Valérie Audinot; A Renouard-Try; Philippe Beauverger; Christelle Macia; C Ouvry; Nadine Nagel; Herve RIQUE; Jean A Boutin; Jean-Pierre Galizzi
Genomic organization and characterization of splice variants of the human histamine H3 receptor.
The Biochemical journal 2001;355(Pt 2):279-88.
2001: Alex Cordi; I Berque-Bestel; T Persigand; Jean-Michel Lacoste; Adrian Newman-Tancredi; Valérie Audinot; Mark J Millan
Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties.
Journal of medicinal chemistry 2001;44(5):787-805.
2001: Valérie Audinot; Adrian Newman-Tancredi; Mark J Millan
Constitutive activity at serotonin 5-HT(1D) receptors: detection by homologous GTPgammaS versus [(35)S]-GTPgammaS binding isotherms.
Neuropharmacology 2001;40(1):57-64.
2000: Mark J Millan; Anne Dekeyne; Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; G Milligan; Delphine Duqueyroix; Sylvie Girardon; J Mullot; Jean A Boutin; Jean-Paul Nicolas; A Renouard-Try; Jean-Michel Lacoste; Alex Cordi
S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.
The Journal of pharmacology and experimental therapeutics 2000;295(3):1192-205.
2000: Adrian Newman-Tancredi; Valérie Audinot; C Moreira; Laurence Verrièle; Mark J Millan
Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT(1B) receptor/G-protein stoichiometry.
Molecular pharmacology 2000;58(5):1042-9.
2000: Mark J Millan; Alain Gobert; Adrian Newman-Tancredi; Françoise Lejeune; Didier Cussac; Jean-Michel Rivet; Valérie Audinot; T Dubuffet; Gilbert Lavielle
S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.
The Journal of pharmacology and experimental therapeutics 2000;293(3):1048-62.
2000: Mark J Millan; Adrian Newman-Tancredi; Valérie Audinot; Didier Cussac; Françoise Lejeune; Jean-Paul Nicolas; Francis Cogé; Jean-Pierre Galizzi; Jean A Boutin; Jean-Michel Rivet; Anne Dekeyne; Alain Gobert
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
Synapse (New York, N.Y.) 2000;35(2):79-95.
2000: Mark J Millan; Valérie Audinot; P Honoré; K Bervoets; Sylvie Veiga; Mauricette Brocco
Blockade of NMDA receptors in the nucleus accumbens elicits spontaneous tail-flicks in rats.
European journal of pharmacology 2000;388(1):37-47.
2000: Mark J Millan; Mauricette Brocco; Jean-Michel Rivet; Valérie Audinot; Adrian Newman-Tancredi; L Maiofiss; S Queriaux; Nicole Despaux; Jean-Louis Peglion; Anne Dekeyne
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
The Journal of pharmacology and experimental therapeutics 2000;292(1):54-66.
2000: Mark J Millan; Alain Gobert; Adrian Newman-Tancredi; Françoise Lejeune; Didier Cussac; Jean-Michel Rivet; Valérie Audinot; A Adhumeau; Mauricette Brocco; Jean-Paul Nicolas; Jean A Boutin; Nicole Despaux; Jean-Louis Peglion
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
The Journal of pharmacology and experimental therapeutics 2000;292(1):38-53.
1999: Mark J Millan; Mauricette Brocco; Alain Gobert; F Joly; K Bervoets; Jean-Michel Rivet; Adrian Newman-Tancredi; Valérie Audinot; S Maurel
Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat.
The European journal of neuroscience 1999;11(12):4419-32.
1999: Mark J Millan; Alain Gobert; Valérie Audinot; Anne Dekeyne; Adrian Newman-Tancredi
Inverse agonists and serotonergic transmission: from recombinant, human serotonin (5-HT)1B receptors to G-protein coupling and function in corticolimbic structures in vivo.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1999;21(2 Suppl):61S-67S.
1999: T Dubuffet; Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; A Loutz; Mark J Millan; Gilbert Lavielle
Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist.
Bioorganic & medicinal chemistry letters 1999;9(14):2059-64.
1999: Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; Mark J Millan
Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors.
Naunyn-Schmiedeberg's archives of pharmacology 1999;359(6):447-53.
1999: Alex Cordi; Jean-Michel Lacoste; Valérie Audinot; M Millan
Design, synthesis and structure-activity relationships of novel strychnine-insensitive glycine receptor ligands.
Bioorganic & medicinal chemistry letters 1999;9(10):1409-14.
1999: Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; Valérie Pasteau; S Gavaudan; Mark J Millan
G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: A guanosine-5'-O-(3-[35S]thio)- triphosphate binding and antibody study.
Molecular pharmacology 1999;55(3):564-74.
1998: Valérie Audinot; Adrian Newman-Tancredi; Alain Gobert; Jean-Michel Rivet; Mauricette Brocco; Françoise Lejeune; L Gluck; I Desposte; K Bervoets; Anne Dekeyne; Mark J Millan
A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
The Journal of pharmacology and experimental therapeutics 1998;287(1):187-97.
1998: Mark J Millan; Adrian Newman-Tancredi; Mauricette Brocco; Alain Gobert; Françoise Lejeune; Valérie Audinot; Jean-Michel Rivet; rudy schreiber; Anne Dekeyne; Michael Spedding; Jean-Paul Nicolas; Jean-Louis Peglion
S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
The Journal of pharmacology and experimental therapeutics 1998;287(1):167-86.
1998: Mark J Millan; Alain Gobert; Adrian Newman-Tancredi; Valérie Audinot; Françoise Lejeune; Jean-Michel Rivet; Didier Cussac; Jean-Paul Nicolas; O Muller; Gilbert Lavielle
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
The Journal of pharmacology and experimental therapeutics 1998;286(3):1341-55.
1998: Adrian Newman-Tancredi; S Gavaudan; C Conte; C Chaput; Manuelle Touzard; Laurence Verrièle; Valérie Audinot; Mark J Millan
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
European journal of pharmacology 1998;355(2-3):245-56.
1998: Adrian Newman-Tancredi; Jean-Paul Nicolas; Valérie Audinot; S Gavaudan; Laurence Verrièle; Manuelle Touzard; C Chaput; N Richard; Mark J Millan
Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors.
Naunyn-Schmiedeberg's archives of pharmacology 1998;358(2):197-206.
1998: Alain Gobert; Jean-Michel Rivet; Valérie Audinot; Adrian Newman-Tancredi; Laetitia Cistarelli; Mark J Millan
Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release.
Neuroscience 1998;84(2):413-29.
1997: Adrian Newman-Tancredi; Valérie Audinot; C Chaput; Laurence Verrièle; Mark J Millan
[35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
The Journal of pharmacology and experimental therapeutics 1997;282(1):181-91.
1997: Mark J Millan; Adrian Newman-Tancredi; Jean-Michel Rivet; Mauricette Brocco; P Lacroix; Valérie Audinot; Laetitia Cistarelli; Alain Gobert
S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
The Journal of pharmacology and experimental therapeutics 1997;282(1):132-47.
1997: Valérie Audinot; S Lochon; Adrian Newman-Tancredi; Gilbert Lavielle; Mark J Millan
Binding profile of the novel 5-HT1B/1D receptor antagonist, [3H]GR 125,743, in guinea-pig brain: a comparison with [3H]5-carboxamidotryptamine.
European journal of pharmacology 1997;327(2-3):247-56.
1997: Françoise Lejeune; Adrian Newman-Tancredi; Valérie Audinot; Mark J Millan
Interactions of (+)- and (-)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats.
The Journal of pharmacology and experimental therapeutics 1997;280(3):1241-9.
1995: Adrian Newman-Tancredi; Valérie Audinot; V Jacques; Jean-Louis Peglion; Mark J Millan
[3H](+)S 14297: a novel, selective radioligand at cloned human dopamine D3 receptors.
Neuropharmacology 1995;34(12):1693-6.
1995: Alain Gobert; Jean-Michel Rivet; Valérie Audinot; Laetitia Cistarelli; Michael Spedding; J Vian; Jean-Louis Peglion; Mark J Millan
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
The Journal of pharmacology and experimental therapeutics 1995;275(2):899-913.
1995: Jean-Louis Peglion; H Canton; K Bervoets; Valérie Audinot; Mauricette Brocco; Alain Gobert; S Le Marouille-Girardon; Mark J Millan
Characterization of potent and selective antagonists at postsynaptic 5-HT1A receptors in a series of N4-substituted arylpiperazines.
Journal of medicinal chemistry 1995;38(20):4044-55.
1995: Mark J Millan; Valérie Audinot; C Melon; Adrian Newman-Tancredi
Evidence that dopamine D3 receptors participate in clozapine-induced hypothermia.
European journal of pharmacology 1995;280(2):225-9.
1995: Mark J Millan; Jean-Michel Rivet; Valérie Audinot; Alain Gobert; Françoise Lejeune; Mauricette Brocco; Adrian Newman-Tancredi; S Maurel-Remy; K Bervoets
Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivo.
The Journal of pharmacology and experimental therapeutics 1995;273(3):1418-27.
1995: Alain Gobert; Françoise Lejeune; Jean-Michel Rivet; Valérie Audinot; Adrian Newman-Tancredi; Mark J Millan
Modulation of the activity of central serotoninergic neurons by novel serotonin1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats.
The Journal of pharmacology and experimental therapeutics 1995;273(3):1032-46.
1995: rudy schreiber; Mauricette Brocco; Valérie Audinot; Alain Gobert; Sylvie Veiga; Mark J Millan
(1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists.
The Journal of pharmacology and experimental therapeutics 1995;273(1):101-12.
1994: Jean-Michel Rivet; Valérie Audinot; Alain Gobert; Jean-Louis Peglion; Mark J Millan
Modulation of mesolimbic dopamine release by the selective dopamine D3 receptor antagonist, (+)-S 14297.
European journal of pharmacology 1994;265(3):175-7.
1994: Mark J Millan; Valérie Audinot; Jean-Michel Rivet; Alain Gobert; J Vian; J F Prost; Michael Spedding; Jean-Louis Peglion
S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats.
European journal of pharmacology 1994;260(2-3):R3-5.
1994: F Lejeune; Valérie Audinot; Alain Gobert; Jean-Michel Rivet; Michael Spedding; M J Millan
Clozapine inhibits serotoninergic transmission by an action at alpha 1-adrenoceptors not at 5-HT1A receptors.
European journal of pharmacology 1994;260(1):79-83.
1994: Mark J Millan; H Canton; Alain Gobert; Françoise Lejeune; Jean-Michel Rivet; K Bervoets; Mauricette Brocco; P Widdowson; T Mennini; Valérie Audinot
Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonists.
The Journal of pharmacology and experimental therapeutics 1994;268(1):337-52.
1993: Didier Cussac; L Caccavelli; I Pellegrini; Valérie Audinot; Philippe Jaquet; Alain Enjalbert
[Membrane receptors and coupling proteins in adenohypophyseal cells].
Comptes rendus des séances de la Société de biologie et de ses filiales 1993;187(1):14-23.
1992: L Caccavelli; Didier Cussac; I Pellegrini; Valérie Audinot; Philippe Jaquet; Alain Enjalbert
D2 dopaminergic receptors: normal and abnormal transduction mechanisms.
Hormone research 1992;38(1-2):78-83.